back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-09-30 10:12 Tx date 2024-09-25 |
$LSL
LSL Pharma Group Inc. |
Mainville, Luc
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,270 vol |
1,480,270 | |
| Filed 2024-09-28 23:03 Tx date 2024-09-25 |
$LSL
LSL Pharma Group Inc. |
Fowler, Stuart William
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$67,500
+150,000 vol $0.45 each |
150,000 | |
| Filed 2024-09-28 22:59 Tx date 2024-06-28 |
$LSL
LSL Pharma Group Inc. |
Fowler, Stuart William
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-09-28 12:36 Tx date 2024-09-25 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$6,750
+15,000 vol $0.45 each |
165,000 | |
| Filed 2024-09-28 05:05 Tx date 2024-09-25 |
$LSL
LSL Pharma Group Inc. |
Dellafera, Frank J.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$13,500
+30,000 vol $0.45 each |
280,000 | |
| Filed 2024-09-28 04:54 Tx date 2024-09-25 |
$LSL
LSL Pharma Group Inc. |
Pierre B., Lafrenière
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$13,500
+30,000 vol $0.45 each |
180,000 | |
| Filed 2024-09-28 04:47 Tx date 2024-09-25 |
$LSL
LSL Pharma Group Inc. |
Soccodato, Giuseppe
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$67,500
+150,000 vol $0.45 each |
150,000 | |
| Filed 2024-09-28 04:43 Tx date 2024-09-25 |
$LSL
LSL Pharma Group Inc. |
Beaudry, Diane
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$6,750
+15,000 vol $0.45 each |
165,000 | |
| Filed 2024-07-17 14:23 Tx date 2024-06-28 |
$LSL
LSL Pharma Group Inc. |
Soccodato, Giuseppe
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-07-17 14:23 Tx date 2024-06-28 |
$LSL
LSL Pharma Group Inc. |
Soccodato, Giuseppe
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-06-28 09:06 Tx date 2024-06-26 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+250,000 vol |
250,000 | |
| Filed 2024-06-28 09:01 Tx date 2024-04-22 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-06-28 09:00 Tx date 2024-06-26 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
16 - Acquisition or disposition under a prospectus exemption
|
$100,000
+250,000 vol $0.40 each |
250,000 | |
| Filed 2024-06-28 08:53 Tx date 2024-04-22 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-05-03 14:25 Tx date 2024-04-29 |
$LSL
LSL Pharma Group Inc. |
Mainville, Luc
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$502,000
+1,255,000 vol $0.40 each |
1,405,000 | |
| Filed 2024-05-01 16:55 Tx date 2024-04-29 |
$LSL
LSL Pharma Group Inc. |
Beaudry, Diane
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+150,000 vol $0.40 each |
150,000 | |
| Filed 2024-05-01 16:52 Tx date 2024-04-22 |
$LSL
LSL Pharma Group Inc. |
Beaudry, Diane
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-04-30 10:43 Tx date 2024-04-29 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+150,000 vol $0.40 each |
150,000 | |
| Filed 2024-04-30 10:39 Tx date 2024-04-22 |
$LSL
LSL Pharma Group Inc. |
Paradis, Mario
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-04-26 18:14 Tx date 2024-04-23 |
$LSL
LSL Pharma Group Inc. |
Dellafera, Frank J.
4 - Director of Issuer
Holder: Alfera Pharmaceuticals, LLC (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$875,000
+1,250,000 vol $0.70 each |
1,271,428 | |
| Filed 2024-04-26 18:12 Tx date 2024-04-23 |
$LSL
LSL Pharma Group Inc. |
Dellafera, Frank J.
4 - Director of Issuer
Holder: Alfera Pharmaceuticals, LLC (Indirect Ownership)
|
Common Shares catégorie A
16 - Acquisition or disposition under a prospectus exemption
|
$500,000
+1,250,000 vol $0.40 each |
1,292,857 | |
| Filed 2024-03-26 15:12 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Holder: Gestion Jacques Grimard Inc. (Indirect Ownership)
|
Warrants
11 - Acquisition or disposition carried out privately
|
+4,692,500 vol |
4,892,500 | |
| Filed 2024-03-26 15:11 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Holder: Gestion Jacques Grimard Inc. (Indirect Ownership)
|
Common Shares catégorie A
11 - Acquisition or disposition carried out privately
|
$1,877,000
+4,692,500 vol $0.40 each |
8,125,000 | |
| Filed 2024-03-26 15:09 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Holder: Gestion Jacques Grimard Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
200,000 | ||
| Filed 2024-03-26 15:08 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Holder: Gestion Jacques Grimard Inc. (Indirect Ownership)
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
3,432,500 | ||
| Filed 2024-03-26 15:07 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
2,405,000 | ||
| Filed 2024-03-25 16:39 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Holder: Gestion Jacques Grimard Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-03-25 16:38 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Holder: Gestion Jacques Grimard Inc. (Indirect Ownership)
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-03-25 16:29 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-03-25 16:39 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Holder: Gestion Jacques Grimard Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-03-25 16:38 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Holder: Gestion Jacques Grimard Inc. (Indirect Ownership)
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-03-25 16:29 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Grimard, Jacques
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-03-19 14:57 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Mainville, Luc
5 - Senior Officer of Issuer
Holder: Chantal Bourgoing (Indirect Ownership)
|
Warrants
11 - Acquisition or disposition carried out privately
|
+875,000 vol |
875,000 | |
| Filed 2024-03-19 14:53 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Mainville, Luc
5 - Senior Officer of Issuer
Holder: Chantal Bourgoing (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-03-19 14:53 Tx date 2024-03-18 |
$LSL
LSL Pharma Group Inc. |
Mainville, Luc
5 - Senior Officer of Issuer
Holder: Chantal Bourgoing (Indirect Ownership)
|
Common Shares catégorie A
11 - Acquisition or disposition carried out privately
|
$350,000
+875,000 vol $0.40 each |
875,000 | |
| Filed 2024-03-19 14:51 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Mainville, Luc
5 - Senior Officer of Issuer
Holder: Chantal Bourgoing (Indirect Ownership)
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-12-27 23:44 Tx date 2023-12-08 |
$LSL
LSL Pharma Group Inc. |
Roberge, François
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Debentures
16 - Acquisition or disposition under a prospectus exemption
|
$
+$85,000 vol $10.00 each |
$85,000 | |
| Filed 2023-12-08 14:41 Tx date 2023-12-08 |
$LSL
LSL Pharma Group Inc. |
Roberge, François
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Debentures
16 - Acquisition or disposition under a prospectus exemption
|
$
+$8,500 vol $10.00 each |
||
| Filed 2023-12-08 14:41 Tx date 2023-12-08 |
$LSL
LSL Pharma Group Inc. |
Roberge, François
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Debentures
16 - Acquisition or disposition under a prospectus exemption
|
$
+$8,500 vol $10.00 each |
$8,500 | |
| Filed 2023-12-08 14:35 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Roberge, François
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Debentures
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-03-04 06:33 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+150,000 vol |
150,000 | |
| Filed 2023-03-04 00:53 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Richer, Sylvain
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
750,000 | ||
| Filed 2023-03-04 00:53 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Richer, Sylvain
5 - Senior Officer of Issuer
Holder: Placements Sylvain Richer Inc. (Indirect Ownership)
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
1,000,000 | ||
| Filed 2023-03-04 00:45 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Boudreault, Marc
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
750,000 | ||
| Filed 2023-03-04 00:45 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Boudreault, Marc
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
1,013,000 | ||
| Filed 2023-03-04 00:44 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Boudreault, Marc
5 - Senior Officer of Issuer
Holder: Fiducie Boudreault Decoste (Indirect Ownership)
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
1,480,000 | ||
| Filed 2023-03-04 00:34 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Pierre B., Lafrenière
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
150,000 | ||
| Filed 2023-03-04 00:04 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Aird, Sylvain
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
150,000 | ||
| Filed 2023-03-04 00:04 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Aird, Sylvain
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
35,714 | ||
| Filed 2023-03-04 00:03 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Aird, Sylvain
4 - Director of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
71,428 | ||
| Filed 2023-03-03 23:54 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Roberge, François
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
4,748,000 | ||
| Filed 2023-03-03 23:48 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Dellafera, Frank J.
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
250,000 | ||
| Filed 2023-03-03 23:47 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Dellafera, Frank J.
4 - Director of Issuer
Holder: Alfera Pharmaceuticals, LLC (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
21,428 | ||
| Filed 2023-03-03 23:47 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Dellafera, Frank J.
4 - Director of Issuer
Holder: Alfera Pharmaceuticals, LLC (Indirect Ownership)
|
Common Shares catégorie A
00 - Opening Balance-Initial SEDI Report
|
42,857 | ||
| Filed 2023-03-03 16:48 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+150,000 vol |
||
| Filed 2023-03-03 16:48 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+150,000 vol |
150,000 | |
| Filed 2023-03-03 07:12 Tx date 2023-02-22 |
$LSL
LSL Pharma Group Inc. |
Mainville, Luc
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|